Oncosil Medical
Oncosil Medical is a medical device company focused on the development and commercialization of innovative cancer treatments. Their primary product, OncoSil, is a brachytherapy device containing radioactive phosphorus-32, designed for the treatment of locally advanced pancreatic cancer. The company aims to improve patient outcomes and quality of life through targeted radiation therapy.
Short position
Oncosil Medical (ASX:OSL) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 66 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.69% in December 2024. OSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Oncosil Medical (OSL) company profile
Profile, insiders and operations
Company
AI-generated research profile of Oncosil Medical
OSL intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links